Key points from article :
California-based Turn Biotechnologies, a company developing treatments to repair aging tissues at the cellular level, has partnered with South Korean pharmaceutical company HanAll Biopharma to develop new treatments for age-related eye and ear conditions.
Turn Bio's technology uses a specific combination of molecules to restore youthful function to cells, and the company has recently received positive feedback from the FDA on a potential skin rejuvenation therapy.
The new partnership will focus on developing similar therapies for eye and ear conditions, with the potential to significantly improve the lives of older patients.
This agreement expands on a previous investment HanAll made in Turn Bio and represents a significant step forward in the field of regenerative medicine.
